Stock Price

As MarketAxess preps its Q4 results, investors weigh a mixed 2025. Will its strategic shifts in a volatile fixed-income market deliver on growth promises?

The biotech firm now expects Phase 2 results in Q3 2026, accelerating hope for new CNS treatments and signaling strong operational momentum to investors.

As Valneva meets investors, all eyes are on its pivotal Lyme disease vaccine data, a potential game-changer for public health and the company's future.

Vera Therapeutics' novel IgAN drug gets FDA fast-track review, promising a new at-home treatment for a debilitating autoimmune kidney disease.

Facing declining revenue but armed with a strong AI vision, Unisys CEO Mike Thomson prepares to address investors at the critical Needham Growth Conference.

Gyre Therapeutics secures a pivotal conditional approval pathway in China for its novel liver fibrosis drug, offering hope for millions of hepatitis B patients.

A successful demonstration of Revoltz's compact electric cargo vehicle to Israeli officials could signal a major shift in last-mile logistics.

With $13.2 billion in assets and 3.41% of all ETH, Bitmine is on a quest for market dominance. A crucial shareholder vote will decide its future.

With a promising schizophrenia drug stalled by FDA requirements and finances tight, Reviva Pharmaceuticals' upcoming presentation is more than just a talk.

EUDA Health's new Helixé 2.0 supplement boasts enhanced potency, nano-delivery tech, and Halal certification to capture the booming global wellness market.

A major acquisition turned sour, a 25% stock crash, and now a class action lawsuit. Inside Perrigo's costly infant formula venture and what it means.

Newly public AI firm Fusemachines unveils an ambitious 2026 growth plan, but faces significant financial hurdles and deep investor skepticism.

As Simply Good Foods preps its Q1 report, investors weigh Quest's strong growth against the ongoing struggles of its Atkins brand and market pressures.

The Nasdaq-listed restaurant operator confirms its board and auditor, signaling stability as it navigates a volatile stock performance and dynamic F&B sector.

Pfizer projects lower 2026 earnings as COVID sales wane and patents expire, shifting focus to a multi-billion dollar R&D push for future growth.

A decade-long wait ends as the FDA approves a new 1st-line therapy for HER2+ breast cancer. See how ENHERTU reshapes patient outcomes and market dynamics.

Aligos Therapeutics is using strategic stock grants to lure top talent. Is this a savvy growth play or a creeping cost for shareholders? We break it down.

MMTEC dodged delisting, but a one-year Nasdaq monitor and a history of reverse splits raise questions about its long-term viability on US exchanges.

Following stellar clinical data, Terns Pharmaceuticals' upsized $650M offering signals massive investor confidence and funds its push to disrupt the CML market.

With its finances in distress, Netcapital bets its future on blockchain and a new CEO. Can a turnaround specialist navigate the crypto frontier?